KNSA

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) | Rumor.io

Kiniksa Pharmaceuticals International

KNSA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,032

Bullish sentiment (50-day avg)100%

Price to earnings ratio75.8

Market capitalization5.9B

Earnings per share0.99

Dividend yield (TTM)—

Revenue (annual)677.6M

Net income (annual)59M

Social

What share of all stock conversation is about KNSA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 29

Kiniksa Pharmaceuticals' ($KNSA) stock surged +23.8% following strong quarterly clinical milestones and commercial execution.
Analysts have raised their price targets for Kiniksa Pharmaceuticals, with Citigroup setting a target of $100, Wedbush at $99, and JPMorgan at $107.
Kiniksa Pharmaceuticals reported Q2'26 results, including revenue of $243.6M and diluted EPS of $0.30, with the company raising its full-year 2026 ARCALYST net product revenue guidance to $980M to $995M.

Generated by AI

Sentiment

Of the messages about KNSA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	96.3% +1.36
Bearish	—	—	0% 0	3.7% -1.36

Bullish· Jul 28

The stock has reached a new 52-week high after crushing Q2 earnings with a 24.83% gain, and the company has raised its FY26 sales guidance above estimates.
Kiniksa Pharmaceuticals' Q2 results showed a 55% YoY increase in revenues, and the commercial flywheel is becoming a reality, not just a story.
The company's strong Q2 earnings beat and raised guidance indicate stronger-than-previously expected operating performance and future cash generation, with a full AI impact map available for further analysis.

Bearish· Dec 28

The company's COVID-19 antibody therapy did not meet the main goal in a late-stage trial.
Goldman Sachs believes the news is a setback for the company's plans to accelerate the development of its COVID-19 related ARDS indication.
The stock price has decreased by as much as 8.9% following the failed trial.

Generated by AI

Topics

Of the messages about KNSA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	39.57%	28.91%
Announcements	—	—	60.43%	50.25%
Analysts	—	—	0%	8.74%
Earnings	—	—	0%	4.87%
Macro	—	—	0%	7.23%
Controversies	—	—	0%	0%

Analysts· Mar 19

Bank of America upgraded Kiniksa Pharmaceuticals' target price from $35 to $37, indicating strong analyst confidence in the company.
Analysts are expecting significant sales growth for Kiniksa's Arcalyst, with estimates ranging from $20M to $385M.
The average 12-month price target for Kiniksa is $31.67, with a buy consensus of 100% among analysts.

Announcements· Aug 3

Kiniksa Pharmaceuticals, Ltd. (KNSA) announces global license agreement with Genentech for Vixarelimab, receiving $100 million upfront and potential development and commercial milestones.
The deal also includes royalties on net sales, which could add up to $600 million.
The agreement is seen as a positive for Kiniksa, allowing the company to focus on Arcalyst commercial execution and explore new opportunities.

Generated by AI

Community

Of the messages about KNSA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	85.67%	73.09%
Newcomers	—	0%	14.33%	26.91%

Regulars· Jul 28

Kiniksa Pharmaceuticals delivered a massive top-line beat in Q2 2026, with ARCALYST product revenue surging 55% YoY to $243.6 million, prompting management to raise FY26 revenue guidance to nearly $1 billion.
Regulars are focusing on Kiniksa Pharmaceuticals' Phase 2 data release for KPL-387, which showed rapid pain reduction with 300 mg SC dosing, and the initiation of the Phase 3 PASTORALE trial.
The company reported better-than-expected Q2 financial results, with revenue of $243.6M up 55.36% YoY and GAAP EPS of $0.33 up 37.50% YoY, leading to a 25%+ candle in a single day.

Newcomers· Jul 28

Kiniksa Pharmaceuticals' ($KNSA) stock price surged +24.9% after the company reported strong Q2 2026 financial results, with a new 52-week high reached.
The company's revenue of $243.6M, primarily driven by ARCALYST, exceeded expectations, and guidance was raised to $980-$995M for 2026 net product revenue.
Kiniksa Pharmaceuticals' Q2 2026 net income of $25.4M and total operating expenses of $216.4M were also notable, with the company's cash and investments reaching $525.9M.

Generated by AI

News

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.

12d agoYahoo Finance

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

Biotech leader Kiniksa stock is poised to hit a new buy point after shares soared 25% in response to better-than-expected sales numbers.

19d agoInvestor's Business Daily

Kiniksa at Wells Fargo conference: arcalyst growth and pipeline deepen

20d agoInvesting.com

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximate

25d agoYahoo Finance

Three Biotech Stocks Stick Out With Their Stellar Charts

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

1mo agoInvestor's Business Daily

Massive Sales Are Expected To Drop — It's All According To Plan

Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining. But the company has a plan.

1mo agoInvestor's Business Daily

Also Discussed

Investors talking about KNSA also mention

#	Name	Attention
1	Cardiol Therapeutics Inc. Class A Common SharesCRDL	0%+0
2	Mirum Pharmaceuticals, Inc.MIRM	0%0
3	BioCryst Pharmaceuticals, Inc.BCRX	0.01%+0
4	KALV - KalVista Pharmaceuticals, Inc.	——
5	Zai Lab Limited ADRZLAB	0%0
6	Sanmina CorporationSANM	0%0
7	PTC Therapeutics, Inc.PTCT	0%new
8	Commvault Systems, Inc.CVLT	0%0
9	Renasant Corp.RNST	0%0
10	Highwoods Properties, Inc.HIW	0%new

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

Healthcare
Drug Manufacturers - Specialty & Generic

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares represents an equity interest in Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company focused on discovering, developing, and commercializing therapies for immune-mediated and inflammatory diseases. The company’s current portfolio centers on products and candidates such as ARCALYST, a marketed interleukin-1 trap used in recurrent pericarditis and related inflammatory conditions, alongside additional clinical-stage programs in immunology and inflammation. Kiniksa serves patients and healthcare providers in the United States, the United Kingdom, and other international markets, with emphasis on specialized treatments for cardiovascular and autoimmune disorders. The company’s role in the healthcare sector is defined by its concentration on targeted biologic medicines that address serious conditions with limited treatment options. Headquartered in London, Kiniksa Pharmaceuticals International, plc operates as a commercial-stage biopharmaceutical business within the global specialty drug market.

Website

Location

105 Piccadilly

London, W1J 7NJ

United Kingdom

Social

What share of all stock conversation is about KNSA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 29

Kiniksa Pharmaceuticals' ($KNSA) stock surged +23.8% following strong quarterly clinical milestones and commercial execution.
Analysts have raised their price targets for Kiniksa Pharmaceuticals, with Citigroup setting a target of $100, Wedbush at $99, and JPMorgan at $107.
Kiniksa Pharmaceuticals reported Q2'26 results, including revenue of $243.6M and diluted EPS of $0.30, with the company raising its full-year 2026 ARCALYST net product revenue guidance to $980M to $995M.

Generated by AI

Sentiment

Of the messages about KNSA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	96.3% +1.36
Bearish	—	—	0% 0	3.7% -1.36

Bullish· Jul 28

The stock has reached a new 52-week high after crushing Q2 earnings with a 24.83% gain, and the company has raised its FY26 sales guidance above estimates.
Kiniksa Pharmaceuticals' Q2 results showed a 55% YoY increase in revenues, and the commercial flywheel is becoming a reality, not just a story.
The company's strong Q2 earnings beat and raised guidance indicate stronger-than-previously expected operating performance and future cash generation, with a full AI impact map available for further analysis.

Bearish· Dec 28

The company's COVID-19 antibody therapy did not meet the main goal in a late-stage trial.
Goldman Sachs believes the news is a setback for the company's plans to accelerate the development of its COVID-19 related ARDS indication.
The stock price has decreased by as much as 8.9% following the failed trial.

Generated by AI

Topics

Of the messages about KNSA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	39.57%	28.91%
Announcements	—	—	60.43%	50.25%
Analysts	—	—	0%	8.74%
Earnings	—	—	0%	4.87%
Macro	—	—	0%	7.23%
Controversies	—	—	0%	0%

Analysts· Mar 19

Bank of America upgraded Kiniksa Pharmaceuticals' target price from $35 to $37, indicating strong analyst confidence in the company.
Analysts are expecting significant sales growth for Kiniksa's Arcalyst, with estimates ranging from $20M to $385M.
The average 12-month price target for Kiniksa is $31.67, with a buy consensus of 100% among analysts.

Announcements· Aug 3

Kiniksa Pharmaceuticals, Ltd. (KNSA) announces global license agreement with Genentech for Vixarelimab, receiving $100 million upfront and potential development and commercial milestones.
The deal also includes royalties on net sales, which could add up to $600 million.
The agreement is seen as a positive for Kiniksa, allowing the company to focus on Arcalyst commercial execution and explore new opportunities.

Generated by AI

Community

Of the messages about KNSA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	85.67%	73.09%
Newcomers	—	0%	14.33%	26.91%

Regulars· Jul 28

Kiniksa Pharmaceuticals delivered a massive top-line beat in Q2 2026, with ARCALYST product revenue surging 55% YoY to $243.6 million, prompting management to raise FY26 revenue guidance to nearly $1 billion.
Regulars are focusing on Kiniksa Pharmaceuticals' Phase 2 data release for KPL-387, which showed rapid pain reduction with 300 mg SC dosing, and the initiation of the Phase 3 PASTORALE trial.
The company reported better-than-expected Q2 financial results, with revenue of $243.6M up 55.36% YoY and GAAP EPS of $0.33 up 37.50% YoY, leading to a 25%+ candle in a single day.

Newcomers· Jul 28

Kiniksa Pharmaceuticals' ($KNSA) stock price surged +24.9% after the company reported strong Q2 2026 financial results, with a new 52-week high reached.
The company's revenue of $243.6M, primarily driven by ARCALYST, exceeded expectations, and guidance was raised to $980-$995M for 2026 net product revenue.
Kiniksa Pharmaceuticals' Q2 2026 net income of $25.4M and total operating expenses of $216.4M were also notable, with the company's cash and investments reaching $525.9M.

Generated by AI

Kiniksa Pharmaceuticals International

Social

Jul 29

Bullish· Jul 28

Bearish· Dec 28

Analysts· Mar 19

Announcements· Aug 3

Regulars· Jul 28

Newcomers· Jul 28

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

Kiniksa at Wells Fargo conference: arcalyst growth and pipeline deepen

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

Three Biotech Stocks Stick Out With Their Stellar Charts

Massive Sales Are Expected To Drop — It's All According To Plan

Also Discussed

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

Company Information

Location

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

Kiniksa at Wells Fargo conference: arcalyst growth and pipeline deepen

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

Three Biotech Stocks Stick Out With Their Stellar Charts

Massive Sales Are Expected To Drop — It's All According To Plan

Also Discussed

Social

Jul 29

Bullish· Jul 28

Bearish· Dec 28

Analysts· Mar 19

Announcements· Aug 3

Regulars· Jul 28

Newcomers· Jul 28